Chemistry:Zelandopam
From HandWiki
Zelandopam (INN; developmental code names YM-435, MYD-37) is a selective dopamine D1-like receptor agonist related to fenoldopam which was under development in Japan for the treatment of hypertension and heart failure but was never marketed.[1][2][3] The drug was being developed for use by intravenous administration.[1] The development of zelandopam appears to have been discontinued by the early 2000s.[1] It was first described in the scientific literature by 1991.[4]
References
- ↑ 1.0 1.1 1.2 "Zelandopam hydrochloride". 22 May 2002. https://adisinsight.springer.com/drugs/800002584.
- ↑ "The therapeutic potential of dopamine modulators on the cardiovascular and renal systems". Expert Opin Investig Drugs 11 (5): 631–644. May 2002. doi:10.1517/13543784.11.5.631. PMID 11996645.
- ↑ "Interactions between the intrarenal dopaminergic and the renin-angiotensin systems in the control of systemic arterial pressure". Clin Sci (Lond) 136 (16): 1205–1227. August 2022. doi:10.1042/CS20220338. PMID 35979889.
- ↑ Giammattei, C. E., Handa, R. K., & Strandhoy, J. W. (1991). The DA1 agonists, YM435 (YM) and fenoldopam (F), inhibit oxygen consumption (QO2) in rat renal proximal tubules. Pharmacologist, 33, 210p. https://scholar.google.com/scholar?cluster=13521937496129958590
 |  |
